Log in to search using one of your social media accounts:

 

Long-Term Remissions of Patients with Follicular Lymphoma Grade 3 Treated with Rituximab, Cyclophospamide, Doxorubicine, Vincristine and Prednisone (R-CHOP)
The optimal management of patients with follicular lymphoma grade 3 (FLG3) is controversial. This is a case series of 45 patients with FLG3 treated with frontline R-CHOP and observed for an extended time interval. The overall response rate was 100% and the median progression-free survival (PFS) has not been reached, with a 3-year PFS of 70%; 14 (31%) patients relapsed, nearly all within 3 years. The baseline characteristic more strongly associated with a shorter PFS were lymph node sites more than 4 and presence of B symptoms. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 14, 2017 Category: Hematology Authors: Paolo Strati, Nathan Fowler, Sergio Pina-Oviedo, L. Jeffrey Medeiros, Michael J. Overman, Jorge E. Romaguera, Loretta Nastoupil, Michael Wang, Fredrick B. Hagemeister, Alma Rodriguez, Yasuhiro Oki, Jason Westin, Francesco Turturro, Sattva S. Neelapu, Luis Source Type: research

Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8 Positive T-Cell Lymphoma
Several studies have suggested that hematopoietic stem cell transplant (HSCT) may provide a cure for Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8 positive T-Cell Lymphoma (CD8+ PCAETL). We summarize published literature on this disease and present outcomes of 8 patients with CD8+ PCAETL treated at our institution. In our experience, allogeneic HSCT and the novel agents brentuximab and pralatrexate demonstrate substantial activity against this disease. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 14, 2017 Category: Hematology Authors: Benoit M. Cyrenne, Juliet Fraser Gibson, Antonio Subtil, Michael Girardi, Iris Isufi, Stuart Seropian, Francine Foss Source Type: research

How to approach a Hodgkin lymphoma patient who relapses after autologous SCT: Allogeneic SCT
Hodgkin lymphoma (HL) is a highly curable B-cell lymphoma, and approximately 90% of patients who present with early stage (I-II) disease (1) and 70% of patients who present with late-stage disease will be cured with standard frontline treatment(2). For patients with relapsed or refractory (r/r) disease after initial therapy, the standard of care is salvage chemotherapy followed by autologous transplant (autoSCT). While this approach will cure a significant proportion of patients, up to 50% of patients will experience disease progression after autoSCT(3), and this population has historically had a very poor prognosis. (Sour...
Source: Clinical Lymphoma, Myeloma and Leukemia - November 14, 2017 Category: Hematology Authors: Matthew Mei, Robert Chen Source Type: research

Efficacy of standard dose R-CHOP alternating with R-HDAC followed by autologous hematopoietic cell transplantation as initial therapy of mantle cell lymphoma, a single institution experience
In a retrospective study of 87 patients with mantle cell lymphoma treated with 3 different induction regimens, we show that a modification of the Nordic regimen in which a standard, rather than dose-intense, R-CHOP alternating with high dose cytarabine is a highly effective pre-autologous hematopoietic cell transplantation therapy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 14, 2017 Category: Hematology Authors: Yazeed Sawalha, Brian T. Hill, Lisa A. Rybicki, Danyu Sun, Robert M. Dean, Deepa Jagadeesh, Betty K. Hamilton, Aaron T. Gerds, Ronald M. Sobecks, Steven Andresen, Hien K. Liu, Navneet S. Majhail, Brad Pohlman, Matt E. Kalaycio, Brian J. Bolwell, Mitchell Source Type: research

A Phase II Trial of Rituximab in Combination with Pegfilgrastim in Patients with Indolent B-Cell Non-Hodgkin ’s Lymphoma
This phase 2 study demonstrates that augmenting neutrophil function by addition of pegfilgrastim can potentiate the clinical activity of rituximab in indolent B-cell non-Hodgkin ’s lymphomas (B-NHL) while retaining its excellent safety profile. Strategies to boost the innate immune system such as this combination warrant further study, especially in the frail, elderly population where therapeutic options are limited due to poor tolerance. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 6, 2017 Category: Hematology Authors: Pallawi Torka, Priyank Patel, Wei Tan, Gregory Wilding, Seema A. Bhat, Myron S. Czuczman, Kelvin P. Lee, George Deeb, Vishala Neppalli, Cory Mavis, Paul Wallace, Francisco J. Hernandez-Ilizaliturri Source Type: research

VcR-CVAD induction chemotherapy followed by maintenance rituximab produces durable remissions in mantle cell lymphoma: a Wisconsin Oncology Network study
VcR-CVAD with maintenance rituximab is an intermediate-intensity regimen for older and younger mantle cell lymphoma (MCL) patients. Thirty patients were treated, with primary end point of response and secondary endpoints of progression-free and overall survival. After a median follow-up of 7.8 years, no relapses were observed beyond 6 years. VcR-CVAD has long-term outcomes comparable with more intensive chemotherapy regimens. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 3, 2017 Category: Hematology Authors: J.E. Chang, L.L. Carmichael, K. Kim, C. Peterson, D.T. Yang, A.M. Traynor, J.E. Werndli, M.S. Huie, T.A. McFarland, M. Volk, J. Blank, N.S. Callander, W.L. Longo, Kahl Source Type: research

Early Relapse for Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Therapy: A Single-center Experience
The purpose of the present study was to understand the effect of early relapse (ER) on the overall survival of myeloma patients. We analyzed the outcomes of 257 patients who had received novel agent-based induction therapy and undergone single autologous stem cell therapy at our center from 2010 to 2016. We have concluded that ER, high-risk cytogenetics, and lactate dehydrogenase> 350 UI/L are significant prognosticators for poor patient outcome in those with multiple myeloma. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 1, 2017 Category: Hematology Authors: Holly Lee, Peter Duggan, Ahsan Chaudhry, Paola Neri, Jason Tay, Fariborz Rashid-Kolvear, Nizar J. Bahlis, Victor H. Jimenez-Zepeda Tags: Original Study Source Type: research

Modified HyperCVAD Versus Bortezomib-HyperCAD in Patients With Relapsed/Refractory Multiple Myeloma
Despite the availability of novel treatments for multiple myeloma, resistance to chemotherapy inevitably develops. We retrospectively reviewed the outcomes of patients with relapsed and/or refractory disease treated with modified hyperCVAD (n = 15) or bortezomib-hyperCAD (n = 18). Effectiveness and safety outcomes were similar in each group, with the entire cohort of patients demonstrating an overall response rate of 42%. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 1, 2017 Category: Hematology Authors: Megan M. Saraceni, Emma Scott, Richard T. Maziarz, Matthew B. Siegel, Solange Bassale, Susie Jiing, Eva Medvedova Tags: Original Study Source Type: research

Early relapse for Multiple Myeloma patients undergoing single auto-SCT: A single center experience
The purpose of this study was to understand the impact of early relapse (ER) on overall survival of myeloma patients. We analyzed the outcomes of 257 patients who received novel agent based inductions and underwent single auto-SCT at our center between 2010 and 2016. We conclude that ER, high-risk cytogenetics, and LDH>350 UI/L are significant prognosticators for poor patient outcome in multiple myeloma. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 1, 2017 Category: Hematology Authors: Holly Lee, Peter Duggan, Ahsan Chaudhry, Paola Neri, Jason Tay, Fariborz Rashid-Kolvear, Nizar J. Bahlis, Victor H. Jimenez-Zepeda Tags: Original Study Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 29, 2017 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 29, 2017 Category: Hematology Source Type: research

Advances in Diagnosis and Management of Diffuse Large B-cell Lymphoma
The management of diffuse large B-cell lymphoma (DLBCL) has been gradually evolving since the discovery of its 2 major forms, the germinal center B-like (GCB) and activated B-cell (ABC) types. Although the reference standard for the identification of these cell types is considered gene expression profiling (GEP), currently the only method commercially available is immunohistochemistry (IHC). The application of various IHC-based algorithms and their correlation with GEP and clinical outcome are discussed. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 26, 2017 Category: Hematology Authors: Fernando Cabanillas, Bijal Shah Tags: Review Source Type: research

Advances in Diagnosis and Management of Diffuse Large B Cell Lymphoma
The management of diffuse large B cell lymphoma (DLBCL) has been gradually evolving since the discovery of its two major forms, the germinal cell (GCB) and activated B cell (ABC) types. Although the “gold standard” for the identification of these cell types is considered to be gene expression profiling (GEP), currently the only method commercially available is immunohistochemistry (IHC). The application of various IHC based algorithms is discussed as well as their correlation with GEP and w ith clinical outcome. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 26, 2017 Category: Hematology Authors: Fernando Cabanillas, Bijal Shah Source Type: research

State of the Art Update and Next Questions: Acute Myeloid Leukemia
The past decade has witnessed major advances in our comprehension of the biological heterogeneity of acute myeloid leukemia (AML); however, translating this knowledge into better outcomes for AML patients has lagged. Over the past year, two large, randomized phase III clinical trials with novel therapies produced positive results that are expected to lead to the first new drug approvals in AML in over 40 years.[1, 2] Many other promising drugs are currently under investigation, offering hope that even more novel treatments will be added to the armamentarium in the near future. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 19, 2017 Category: Hematology Authors: Kendra Sweet, Jeffrey Lancet Tags: Review Article Source Type: research

A Systematic Review of Treatments of Relapsed/Refractory Mantle Cell Lymphoma
A systematic review was conducted to evaluate the clinical effectiveness and safety of treatments for patients with relapsed/refractory mantle cell lymphoma (MCL) unsuitable for intensive treatment. The criteria for inclusion of the trials were established before the review. A search of Medline, Embase, and the Cochrane library databases was conducted to identify phase II or III randomized controlled trials (RCTs), reported from January 1, 1994 to May 29, 2016. Relevant conference abstracts, citation lists from the included articles, published guidelines, and on-going clinical trial databases were also searched. (Source: C...
Source: Clinical Lymphoma, Myeloma and Leukemia - October 13, 2017 Category: Hematology Authors: Madeliene Parrott, Simon Rule, Michael Kelleher, Jayne Wilson Tags: Review Source Type: research

A Systematic Review of Treatments for Relapsed/Refractory Mantle Cell Lymphoma
A systematic literature review was conducted to evaluate the clinical effectiveness and safety of treatments for patients with relapsed/refractory mantle cell lymphoma (MCL) unsuitable for intensive treatment. Criteria for inclusion of trials were established prior to the literature review. A search of Medline, Embase and the Cochrane library databases was conducted to identify phase II or III randomised controlled trials (RCTs), published from January 1st 1994 to 29th May 2016. Relevant conference abstracts, citation lists from included articles, published guidelines and on-going clinical trial databases were also searche...
Source: Clinical Lymphoma, Myeloma and Leukemia - October 13, 2017 Category: Hematology Authors: Madeliene Parrott, Simon Rule, Michael Kelleher, Jayne Wilson Source Type: research

Management of Advanced and Relapsed/Refractory Extra-Nodal Natural Killer T-Cell Lymphoma (ENKL): An Analysis of Stem Cell Transplant and Chemotherapy Outcomes
Extra-nodal natural killer/T-cell lymphoma (ENKL) is a rare lymphoma representing approximately 5-10% of T-cell non-Hodgkin lymphomas diagnosed in the United States each year.1, 2 ENKL is universally associated with Epstein-Barr virus (EBV) infection, and is more frequent in Asian, Central American and South American populations, where it constitutes 5-15% of all lymphomas.3-5 Patients with advanced stage ENKL (stage III-IV) and relapsed/refractory early stage disease are treated with systemic chemotherapy with or without radiotherapy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 11, 2017 Category: Hematology Authors: Jonathan E. Brammer, Dai Chihara, L. Michelle Poon, Paolo Caimi, Marcos de Lima, Celina Ledesma, Gabriela Rondon, Stefan O. Ciurea, Yago Nieto, Michele Fanale, Bouthaina Dabaja, Richard T. Maziarz, Richard E. Champlin, Chitra Hosing, Yasuhiro Oki Source Type: research

Allogeneic hematopoietic cell transplantation for Richter syndrome: a single-center experience
⁃ Allogeneic hematopoietic cell transplantation is an effective therapy in patients with Richter syndrome. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 11, 2017 Category: Hematology Authors: Mohamed A. Kharfan-Dabaja, Ambuj Kumar, Facundo E. Stingo, Farhad Khimani, Mohammad Hussaini, Ernesto Ayala, Taiga Nishihori, Bijal Shah, Frederick L. Locke, Javier Pinilla-Ibarz, Julio C. Chavez Source Type: research

Are we Choosing Wisely in lymphoma? Excessive use of surveillance CT imaging in patients with diffuse large B-cell lymphoma (DLBCL) in long-term remission
The use of surveillance computed tomography (CT) imaging in patients with diffuse large B-cell lymphoma (DLBCL) in remission is neither effective nor cost-effective. The American Society of Hematology (ASH) Choosing Wisely (CW) campaign, in particular, emphasizes the lack of benefit beyond 2-years of completion of therapy. We sought to describe the real-world practice of surveillance imaging. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 9, 2017 Category: Hematology Authors: Matthew C. Cheung, Nicole Mittmann, Craig C. Earle, Farah Rahman, Ning Liu, Simron Singh Tags: Original Study Source Type: research

Hereditary Hemochromatosis Manifesting After Treatment of Paroxysmal Nocturnal Hemoglobinuria with Eculizumab
Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare clonal hematopoietic stem cell disorder caused by an acquired somatic mutation in one of the genes required for synthesis of glycosylphosphatidylinositol (GPI), an anchoring protein.1 –8 GPI binds several proteins to the cell including CD55 and CD59, which inhibit cellular destruction by the alternate complement pathway. Without these proteins, PNH erythrocytes are susceptible to hemolysis via the membrane attack complex.1–8 The degree of hemolysis in PNH often exceeds the ha ptoglobin binding capacity of the plasma, resulting in hemoglobinuria. (Source: Clini...
Source: Clinical Lymphoma, Myeloma and Leukemia - October 7, 2017 Category: Hematology Authors: Elizabeth Elliott, Salman Waheed, Sahr Syed, Sheila Eswaran, Stephanie Gregory, Jamile Shammo Tags: Case Report Source Type: research

Two states of myeloma stem cells
The identity of so-called malignant stem cells in multiple myeloma has long been controversial. However, it is now appreciated that a small population of myeloma cells has a stem-like capacity for self-renewal and resides within the population of recognizable myeloma plasma cells, although whether these cells are quiescent or proliferative remains unresolved. It is also now accepted that subpopulations of myeloma plasma cells alternate bidirectionally and dynamically between immature and mature phenotypes, and both subpopulations are capable of clonogenicity in vitro and in animal models. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 3, 2017 Category: Hematology Authors: Shmuel Yaccoby Tags: Perspective Source Type: research

Cast nephropathy and deceptively low absolute serum free light chain levels: resolution of a challenging case and systematic review of the literature
Multiple myeloma (MM) is a hematological malignancy characterized by the accumulation of monoclonal plasma cells (PCs) in the bone marrow (BM). Monoclonal PC proliferation is accompanied by the secretion of a monoclonal protein that serves as a quantitative MM marker and can be detected in the blood and/or urine. The International Myeloma Working Group defined the diagnostic criteria for symptomatic MM, smouldering MM and monoclonal gammopathy of undetermined significance based on biological parameters and presence of clinical symptoms. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 3, 2017 Category: Hematology Authors: Michael P. Rassner, Maximilian Seidl, Ulrich Salzer, S. Vincent Rajkumar, Thomas Epting, Ralph W äsch, Elke Neumann-Haefelin, Monika Engelhardt Tags: Case Report Source Type: research

Long-Term Outcome of Relapsed Adult Philadelphia Chromosome-Positve Acute Lymphoblastic Leukemia Treated with Continuous Imatinib Plus Combination Therapy
acute lymphoblastic leukemia, Philadelphia chromosome positive, relapse, imatinib (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Sung Nam Lim Source Type: research

Targeting the Mitochondria Metabolism of T-ALL with Novel Mitochondrial Complex I Inhibitor IACS-010759
T-ALL, Metabolism, mitochondrial Complex I, Notch1 mutations, Glutaminase (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Natalia Baran, Alessia Lodi, Shannon Sweeney, Vinitha Mary Kuruvilla, Antonio Cavazos, Sriram Shanmuga Velandy, Karine Harutyunyan, Ningping Feng, Jason Gay, Marcin Kaminski, Elias J. Jabbour, Adolfo Ferrando, M. Emilia Di Francesco, Stefano Tiziani, Jose Source Type: research

MCL-1 Up-Regulation through MAPK Activation Confers Acquired Resistance to BCL-2 Inhibitor ABT-199 in Pre-Clinical AML Models
In this study we investigated mechanisms of acquired resistance to venetoclax in preclinical AML models. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Qi Zhang, Lina Han, Rongqing Pan, Ce Shi, Ryan Jeremy, Man Chun John Ma, Steven Kurtz, Hong Mu, Vivian R. Ruvolo, Helen Ma, Yingchang Mi, Jeffrey Tyner, Letai Anthony, Richard Eric Davis, Michael Andreeff, Marina Konopleva Tags: Acute Myeloid Leukemia Source Type: research

Phosphotyrosine-Based Phosphoproteomics of a Panel AML Cell Lines Reveals Oncogenic Signaling and Hyperactive Tyrosine Kinases as Targets for Treatment
Acute myeloid leukemia (AML) is a clonal disorder arising from hematopoietic progenitors developing in the myeloid pathway characterized by deregulated differentiation and maturation programs. In AML, tyrosine kinases have been implicated in leukemogenesis, and are associated with poor treatment outcome. Kinase inhibitor treatment has shown promise in improving patient outcome, however patients may benefit from better patient selection. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Carolien van Alphen, Jacqueline Cloos, Sander R. Piersma, Jaco C. Knol, Thang V. Pham, Johan van Meerloo, Gert J. Ossenkoppele, Henk M.W. Verheul, Jeroen J.W.M. Janssen, Connie R. Jimenez Source Type: research

The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine is Highly Active in Patients (Pts) with  FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial
FLT3-ITD mutation in acute myeloid leukemia (AML) is associated with early relapse and poor survival. Quizartinib inhibits FLT3 kinase activity potently and selectively. In phase I and II studies, the composite response rate was approximately 50% among pts with FLT3-ITD. There is in-vitro synergy between quizartinib and 5-azacitidine (AZA) or low dose cytarabine (LDAC). Adding quizartinib to AZA or LDAC may improve the overall response rate (ORR) and duration expected from the use of either agent alone. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Mahesh Swaminathan, Hagop Kantarjian, Naval Daver, Gautam Borthakur, Maro Ohanian, Tapan Kadia, Courtney DiNardo, Nitin Jain, Zeev Estrov, Alessandra Ferrajoli, Guillermo Garcia-Manero, Marina Konopleva, Michael Andreeff, Naveen Pemmaraju, Elias Jabbour, Source Type: research

Outcomes with Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine as Salvage Therapy for Relapsed/Refractory Acute Myeloid Leukemia
acute myeloid leukemia, decitabine, cytarabine, salvage, relapsed, refractory (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Prajwal Boddu, Nitin Jain, Farhad Ravandi, Guillermo Garcia Manero, Gautam Borthakur, Tapan Kadia, Elias J. Jabbour, Naveen Pemmaraju, Naval Daver, Courtney D. DiNardo, Marina Konopleva, Yesid Alvarado, Koichi Takahashi, Christopher Benton, Allison Pike, Source Type: research

Clinical Experience of Venetoclax Combinations for Relapsed/Refractory Myeloid Malignancies
myeloid malignancies, venetoclax, salvage chemotherapy, low-intensity chemotherapy (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Caitlin R. Rausch, Courtney D. DiNardo, Tapan Kadia, Koichi Takahashi, Nitin Jain, Christopher Benton, Philip Thompson, Maro Ohanian, Wendy Covert, Morgan Mace, Kayleigh R. Marx, Naveen Pemmaraju, Naval Daver, Elias Jabbour, Jorge Cortes, Guillermo Garcia Source Type: research

Evaluation of Fluoroquinolone Versus Other Antibiotic Prophylaxis Strategies in Adult Patients with AML Undergoing Induction Chemotherapy
acute myeloid leukemia, fluoroquinolone, prophylaxis, induction chemotherapy (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Telyssa Anderson, Samuel L. Aitken, Kayleigh Marx, Frank P. Tverdek Source Type: research

Validation of the Myelofibrosis Secondary to PV and ET-Prognostic Model in Newly Diagnosed Patients with Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: MD Anderson Cancer Center
The recently proposed Myelofibrosis Secondary to PV and ET-Prognostic Model (MYSEC-PM) (Passamonti, Leukemia 2017) refines overall survival in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis (PPV, PET-MF) molecularly annotated for JAK2, CALR, and MPL mutations. We aimed to validate the prognostic utility of MYSEC-PM for PET / PPV-MF patients at MD Anderson Cancer Center (MDACC). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Lucia Masarova, Hagop Kantarjian, Srdan Verstovsek Source Type: research

Randomized Phase II Study of Guadecitabine (SGI-110) Based Regimens Comparing Guadecitabine 5 days (SGI5), 10 days (SGI10), 5 days + Idarubicin (SGI5 + Ida), and 5 days + Cladribine (SGI5 + Clad), in Previously Untreated Patients ≥ 70 Years with Acute Myeloid Leukemia (AML)–a Bayesian Design
Guadecitabine is a novel hypomethylating dinucleotide of decitabine and deoxyguanosine resistant to degradation by cytidine deaminase. This allows gradual and prolonged exposure of leukemia cells to its active metabolite, decitabine. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Kiran Naqvi, Garciela Nogueras Gonzalez, Cora Cheung, Naveen Pemmaraju, Elias Jabbour, Guillermo Garcia-Manero, Courtney DiNardo, Maro Ohanian, Nitin Jain, Koichi Takahashi, Yesid Alvarado, Marina Konopleva, Xuelin Huang, Jorge Cortes, Hagop Kantarjian Source Type: research

A Phase IB/II Study of Lirilumab with Azacytidine in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Blockade of inhibitory killer-cell immunoglobulin receptor (KIR) receptors induces augmented NK-cell mediated tumor cell lysis (Romagne F et al., Blood 2009). Hypomethylating agents (HMAs) possess anti-leukemia activity, and increase MHC II expression, cancer antigen exposure in solid and hematologic malignancies, and interferon-gamma signature. KIR-receptor blockade by lirilumab (KIR2DL1/2/3-antibody) may improve responses to HMAs. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Naval Daver, Prajwal Boddu, Farhad Ravandi, Elias Jabbour, Gautam Borthakur, Courtney DiNardo, Marina Konopleva, Naveen Pemmaraju, Tapan Kadia, Nitin Jain, Sherry Pierce, Nawar Hussain, Jing Ning, Graciela Nogueras-Gonzalez, Sreyashi Basu, Jorge Cortes, P Source Type: research

A Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)
AML, selinexor, sorafenib, FLT3-mutation (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Naval Daver, Rita Assi, Farhad Ravandi, Guillermo Garcia-Manero, Elias Jabbour, Courtney D. DiNardo, Tapan M. Kadia, Jing Ning, Graciela Nogueras-Gonzalez, Sherry Pierce, Dan Gombos, Steven Kornblau, Marina Konopleva, Mary Kelly, Gautam Borthakur, Weiguo Source Type: research

Targeting Unc-51 Like Autophagy Activating Kinase 1 (ULK1) in Acute Myeloid Leukemia (AML)
AML, autophagy inhibition, combination therapy, ROS, DNA damage (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Seemana Bhattacharya, Sujan Piya, Teresa McQueen, Marina Konopleva, Michael Andreeff, Gautam Borthakur Source Type: research

Nivolumab (Nivo) in Combination with Azacytidine (AZA) in Relapsed and Frontline Elderly Acute Myeloid Leukemia (AML)
Nivolumab, azacytidine, relapsed AML, frontline AML (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Naval Daver, Guillermo Garcia-Manero, Sreyashi Basu, Jorge Cortes, Farhad Ravandi, Elias Jabbour, Rita Assi, Mark Brandt, Sherry Pierce, Tauna Gordon, Naveen Pemmaraju, Michael Andreeff, Jing Ning, Steven Kornblau, Tapan Kadia, Wilmer Flores, Jairo Matthe Tags: Checkpoint Inhibitors Source Type: research

Th1/17 Hybrid CD4+ Cells Are Expanded in Bronchial Alveolar Lavage Fluid from Leukemia Patients with Checkpoint Inhibitor-Induced Pneumonitis
Leukemia, checkpoint inhibitors, pneumonitis, Th1/17 hybrid CD4+ cells, bronchial alveolar lavage (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Sang Kim, Vickie Shannon, Ajay Sheshadri, Hagop Kantarjian, Guillermo Garcia-Manero, Jin Im, Farhad Ravandi, Aung Naing, Padmanee Sharma, Dimitrios Kontoyiannis, Andrew Futreal, Naval Daver Source Type: research

Improved Acute Graft-versus Host Disease (aGVHD) and Progression Free Survival with Post-Transplant Cyclophosphamide in AML/MDS Patients (pts) with Prior CTLA-4 or PD-1 Blockade
cyclophosphamide, stem cell transplant, nivolumab, ipilimumab, AML (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Bet ül Oran, Guillermo Garcia-Manero, Rima M. Saliba, Gheath Al-Atrash, Elias Jabbour, Uday Popat, Farhad Ravandi, Amin Alousi, Tapan Kadia, Marina Konopleva, Courtney Dinardo, Katy Rezvani, Elizabeth J. Shpall, Padmanee Sharma, Richard E. Champlin, Ha Source Type: research

Mutations of BRAF and BIRC3 Identify a Subgroup of Chronic Lymphocytic Leukemia with Very Poor Prognosis upon FCR Treatment
chronic lymphocytic leukemia, FCR, immunochemotherapy, molecular predictors, precision medicine (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Riccardo Moia, Fary Diop, Chiara Favini, Elisa Spaccarotella, Lorenzo De Paoli, Alessio Bruscaggin, Valeria Spina, Michaela Cerri, Clara Deambrogi, Ahad Ahmed Kodipad, Simone Favini, Sruthi Sagiraju, Clive Jabangwe, Francesca Romana Mauro, Ilaria Del Giud Tags: Chronic Lymphocytic Leukemia Source Type: research

Consolidation Treatment with Lenalidomide Following Front-line or Salvage Chemoimmunotherapy in Chronic Lymphocytic Leukemia
CLL, lenalidomide, consolidation (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Paolo Strati, Michael J. Keating, Jan A. Burger, Susan M. O'Brien, William G. Wierda, Zeev Estrov, Gracy Zacharian, Alessandra Ferrajoli Source Type: research

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) Treatment for First-Line Therapy  of Patients with CLL with Mutated IGHV and Without Deletion 17p
CLL, Chemotherapy, Ibrutinib, Frontline Treatment, Mutated IGHV (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Nitin Jain, Philip Thompson, Jan Burger, Gautam Borthakur, Prithviraj Bose, Zeev Estrov, Alessandra Ferrajoli, Koichi Takahashi, Naveen Garg, Xuemei Wang, Varsha Gandhi, William Plunkett, Rashmi Kanagal-Shamanna, Keyur Patel, Wanda Lopez, Hagop Kantarjian Source Type: research

Efficacy and Safety Outcomes by Baseline Comorbidity and Age in Patients Newly Diagnosed with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Treated with Dasatinib or Imatinib in DASISION
Treatment choice can be affected by patient comorbidities. Retrospective analysis of the phase 3 DASISION study suggested baseline comorbidities did not substantially affect 1-year safety and efficacy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Michael J. Mauro, Jorge E. Cortes, Andreas Hochhaus, Neil P. Shah, Ehab Atallah, Mena Abaskharoun, Oumar Sy, Giuseppe Saglio Tags: Chronic Myelogenous Leukemia Source Type: research

Therapy of Early Chronic Phase Chronic Myeloid Leukemia (CML-CP) with Lower Dose Dasatinib
Dasatinib is a potent tyrosine kinase inhibitor (TKI) of BCR-ABL. Approved dose in the chronic phase is 100mg daily. This is however associated with notable side effects mainly myelosuppression and pleural effusion, leading to dose reductions/interruptions. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Kiran Naqvi, Jorge Cortes, Jeffrey Skinner, Elias Jabbour, Naveen Pemmaraju, Gautam Borthakur, Zeev Estrov, Prithviraj Bose, Philip Thompson, Hagop Kantarjian Source Type: research

Long-Term Outcomes of Early CP CML Patients who have Achieved CCyR but Not MMR after 24 Months on Frontline Imatinib Therapy
Although failure to achieve molecular response milestones on tyrosine kinase inhibitors (TKIs) therapy for chronic phase (CP) chronic myeloid leukemia (CML) means that switching to a different TKI is needed to limit the risk of progression and death, there is insufficient data to show long-term outcomes in the patients who were in a molecular failure after 24 months. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Sung-Eun Lee, Won-Sik Lee, Hyeong-Joon Kim, Jee Hyun Kong, Yunsuk Choi, Young Rok Do, Jae-Yong Kwak, Sukjoong Oh, Sung Hyun Kim, Jeong-A. Kim, Dae Young Zang, Yeung-Chul Mun, Young-Woong Won, Dong-Wook Kim Source Type: research

Cytogenetic and Molecular Failure at 12 Months will be the Optimal Time Point for BCR-ABL1 Tyrosine Kinase Domain Mutation Analysis in Patients with Chronic Myeloid Leukemia: The Analysis Based on 2013 European LeukemiaNet Recommendation
BCR-ABL1 kinase domain mutations are closely related to tyrosine kinase inhibitor (TKI) resistance in chronic myeloid leukemia (CML). Although mutation analysis has been recommended in CML patients with treatment failure, there is no standard guideline according to landmark responses at specific timepoints of European LeukemiaNet (ELN) recommendation. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Hee-Je Kim, Hea-Lyun Yoo, Won-Sik Lee, Hyeong-Joon Kim, Jee Hyun Kong, Yunsuk Choi, Young Rok Do, Jae-Yong Kwak, Sukjoong Oh, Sung Hyun Kim, Jeong-A. Kim, Dae Young Zang, Yeung-Chul Mun, Young-Woong Won, Sung-Eun Lee, Dong-Wook Kim Source Type: research

Characteristics and Outcomes of Malignancy-Associated Hemophagocytic Lymphohistiocytosis (M-HLH) in Adult Patients: A Single-Center Experience
HLH is a systemic condition characterized by inflammatory storm and immune-mediated organ damage. Adult M-HLH is challenging and lethal due to under recognition and diverse presentations. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Rita Assi, Prajwal Boddu, Tapan Kadia, Guillermo Garcia-Manero, Farhad Ravandi, Elias Jabbour, Koichi Takahashi, Marina Konopleva, Abdallah Abou Zahr, Courtney DiNardo, Gautam Borthakur, Nitin Jain, Naveen Pemmaraju, Jing Ning, Sherry Pierce, William Wier Tags: Infection, Inflammation and Cancer Source Type: research

Intercorrelation of Expression of CD56, CD117, CD33, CD20 Antigens with Survival Rates in Patients with Multiple Myeloma in Gomel Region in Belarus
The detection of immunophenotype of plasma cells is very important for diagnosis of multiple myeloma. Mechanism of appearing of different antigens on the surface of malignant plasma cells and their correlation with overall survival isn't sufficiently studied. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Z. Kozich, V. Martinkov, Z. Pugacheva, L. Smirnova Tags: Multiple Myeloma Source Type: research

Molecular Pathophysiology of Myeloma and Clinical Applications
Therapies targeting multiple myeloma (MM) in its bone marrow (BM) microenvironment including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), histone deacetylase (HDAC) inhibitors, and monoclonal antibodies (MoAbs), prolong survival 3 to 4 fold. Novel therapies target ubiquitin proteasome receptor upstream of the proteasome to overcome PI resistance. HDAC6 inhibitors block aggresomal protein degradation and synergize with PIs. IMiDs bind and activate cereblon ubiquitin 3 ligase in MM, with degradation of IZF1/3 and downregulation of Myc and IRF4. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Kenneth Anderson Source Type: research

Elevated Peripheral Blood (4-9%) and Bone Marrow Blasts (5-9%) are Associated with Poor Prognosis in Patients with Primary Myelofibrosis as Well as Post-Essential Thrombocythemia and Post-Polycythemia Vera Myelofibrosis
Patients with accelerated phase (AP) myelofibrosis (MF;>10% blasts in bone marrow [BM] or peripheral blood [PB]) have shorter overall survival (OS) than those in the chronic phase ( (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Lucia Masarova, Hagop M. Kantarjian, Srdan Verstovsek Tags: Myeloproliferative Neoplasms Source Type: research

Editorial Board/Masthead
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Source Type: research